Two new biological drugs (vedolizumab and ustekinumab) and one small molecule
(tofacitinib) have been recently approved for the treatment of inflammatory bowel disease …

The introduction and broad use of new immunosuppressive agents, including biologic
agents and JAK inhibitors, have revolutionised treatment of inflammatory bowel disease …

• Increasingly, pregnant patients with inflammatory or autoimmune diseases use monoclonal
antibody biologics before conception, during pregnancy and while breastfeeding.• A minority …

Background Women with inflammatory bowel diseases (IBD) often receive biologicals
during pregnancy to maintain disease remission. Data on outcome of vedolizumab‐exposed …

Background The prevalence of inflammatory bowel diseases (IBD) is high in women of
childbearing age. Achieving clinical remission from conception to delivery using current …

Background The impact of pregnancy on levels of biologic agents in patients with IBD is
undefined and time to elimination in vedolizumab‐exposed infants is unknown. Aims To …

Inflammatory bowel disease (IBD) poses complex issues in pregnancy, but with high-quality
care excellent pregnancy outcomes are achievable. In this article, we review the current …

The management of inflammatory bowel disease requires continuous medical therapy to
achieve and maintain disease control. Thus, women can be exposed to different drugs …

Background Little is known about the consequences of intrauterine exposure to, and the
post‐natal clearance of, vedolizumab. Aims To investigate the levels of vedolizumab in …

Background Biological agents cross the placenta, resulting in detectable blood levels in the
neonate. Neonatal vaccinations are essential to prevent serious infections. Aim To review …